Ovid Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in thousands, except share and per share data) | September 30,2024 | December 31,2023 |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $15,017 | $27,042 |
| Marketable securities | 47,695 | 78,792 |
| Prepaid expenses and other current assets | 3,115 | 3,763 |
| Total current assets | 65,827 | 109,598 |
| Long-term equity investments | 21,125 | 17,626 |
| Restricted cash | 1,931 | 1,931 |
| Right-of-use asset, net | 13,080 | 13,894 |
| Property and equipment, net | 509 | 769 |
| Other noncurrent assets | 182 | 210 |
| Total assets | $102,654 | $144,027 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,710 | $3,703 |
| Accrued expenses | 7,607 | 6,524 |
| Current portion, lease liability | 1,313 | 1,246 |
| Total current liabilities | 11,630 | 11,473 |
| Long-term liabilities: | ||
| Lease liability | 13,762 | 14,756 |
| Royalty monetization liability | 972 | 30,000 |
| Total liabilities | 26,364 | 56,230 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 71,009,866 and 70,691,992 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 71 | 71 |
| Additional paid-in-capital | 371,228 | 365,591 |
| Accumulated other comprehensive income | 36 | 1 |
| Accumulated deficit | (295,045) | (277,865) |
| Total stockholders’ equity | 76,290 | 87,797 |
| Total liabilities and stockholders’ equity | $102,654 | $144,027 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.